WO2024050019A3 - Procédés de préparation de formes à l'état solide - Google Patents

Procédés de préparation de formes à l'état solide Download PDF

Info

Publication number
WO2024050019A3
WO2024050019A3 PCT/US2023/031719 US2023031719W WO2024050019A3 WO 2024050019 A3 WO2024050019 A3 WO 2024050019A3 US 2023031719 W US2023031719 W US 2023031719W WO 2024050019 A3 WO2024050019 A3 WO 2024050019A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymorphic form
ritonavir
methods
form iii
preparing form
Prior art date
Application number
PCT/US2023/031719
Other languages
English (en)
Other versions
WO2024050019A2 (fr
Inventor
Adrian RADOCEA
Jordan CROOM
Larry R. CHAN
Ami S. BHAVSAR
Pamela A. Smith
Stephen R. Byrn
Stephan D. Parent
Dale K. PURCELL
Original Assignee
Varda Space Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Varda Space Industries, Inc. filed Critical Varda Space Industries, Inc.
Publication of WO2024050019A2 publication Critical patent/WO2024050019A2/fr
Priority to US18/622,657 priority Critical patent/US20240269118A1/en
Publication of WO2024050019A3 publication Critical patent/WO2024050019A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente divulgation concerne une forme polymorphe de ritonavir préparée par l'intermédiaire de nouveaux procédés qui demandent moins de temps pour produire la forme polymorphe, les procédés de préparation de la forme polymorphe, des compositions pharmaceutiques comprenant la forme polymorphe produite par les procédés fournis, ainsi que des méthodes de traitement correspondants avec la forme polymorphe produite par les procédés fournis.
PCT/US2023/031719 2022-09-01 2023-08-31 Procédés de préparation de formes à l'état solide WO2024050019A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/622,657 US20240269118A1 (en) 2022-09-01 2024-03-29 Processes for preparing solid state forms

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263403258P 2022-09-01 2022-09-01
US63/403,258 2022-09-01
US202263404090P 2022-09-06 2022-09-06
US63/404,090 2022-09-06
US202363510042P 2023-06-23 2023-06-23
US63/510,042 2023-06-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/622,657 Continuation US20240269118A1 (en) 2022-09-01 2024-03-29 Processes for preparing solid state forms

Publications (2)

Publication Number Publication Date
WO2024050019A2 WO2024050019A2 (fr) 2024-03-07
WO2024050019A3 true WO2024050019A3 (fr) 2024-04-18

Family

ID=88695473

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/031719 WO2024050019A2 (fr) 2022-09-01 2023-08-31 Procédés de préparation de formes à l'état solide

Country Status (2)

Country Link
US (1) US20240269118A1 (fr)
WO (1) WO2024050019A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7148359B2 (en) * 1998-07-20 2006-12-12 Abbott Laboratories Polymorph of a pharmaceutical
WO2008041176A2 (fr) * 2006-10-03 2008-04-10 Ranbaxy Laboratories Limited Procédé de préparation de la forme i et de la forme ii du ritonavir

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205413B2 (en) 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7148359B2 (en) * 1998-07-20 2006-12-12 Abbott Laboratories Polymorph of a pharmaceutical
WO2008041176A2 (fr) * 2006-10-03 2008-04-10 Ranbaxy Laboratories Limited Procédé de préparation de la forme i et de la forme ii du ritonavir

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEMBURKAR ET AL.: "Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 4, no. 5, 21 June 2000 (2000-06-21), US, pages 413 - 417, XP093117689, ISSN: 1083-6160, DOI: 10.1021/op000023y *
KAWAKAMI ET AL.: "Relationship between Crystallization Tendencies during Cooling from Melt and Isothermal Storage: Toward a General Understanding of Physical Stability of Pharmaceutical Glasses", MOL. PHARMACEUTICS, vol. 11, no. 6, 25 April 2014 (2014-04-25), US, pages 1835 - 1843, XP093116658, ISSN: 1543-8384, DOI: 10.1021/mp400679m *
LI ET AL.: "Ritonavir Revisited: Melt Crystallization Can Easily Find the Late-Appearing Polymorph II and Unexpectedly Discover a New Polymorph III", MOL. PHARMACEUTICS, vol. 20, no. 8, 14 July 2023 (2023-07-14), US, pages 3854 - 3863, XP093116642, ISSN: 1543-8384, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.2c00994> DOI: 10.1021/acs.molpharmaceut.2c00994 *
PARENT ET AL.: "Ritonavir Form III: A Coincidental Concurrent Discovery", CRYS. GROWTH DES., vol. 23, no. 1, 21 December 2022 (2022-12-21), US, pages 320 - 325, XP093116629, ISSN: 1528-7483, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acs.cgd.2c01017> DOI: 10.1021/acs.cgd.2c01017 *
PARENT ET AL.: "Ritonavir Form III: Lightning strikes twice at the same time, 137 miles apart", CHEMRXIV, 8 September 2022 (2022-09-08), pages 1 - 18, XP093116650, Retrieved from the Internet <URL:https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/6317e24e3e2e3657d92d3e00/original/ritonavir-form-iii-lightning-strikes-twice-at-the-same-time-137-miles-apart.pdf> [retrieved on 20240108], DOI: 10.26434/chemrxiv-2022-49tzw *
SNELL; HELLIWELL: "Microgravity as an environment for macromolecular crystallization - an outlook in the era of space stations and commercial space flight", CRYSTALLOGRAPHY REVIEWS, vol. 27, no. 1, 8 April 2021 (2021-04-08), GB, pages 3 - 46, XP093117846, ISSN: 0889-311X, DOI: 10.1080/0889311X.2021.1900833 *
YAO ET AL.: "Ritonavir Form III: A New Polymorph After 24 Years", CHEMRXIV, 18 August 2022 (2022-08-18), pages 1 - 17, XP093117430, Retrieved from the Internet <URL:https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/62fd2557350acf2b9d470215/original/ritonavir-form-iii-a-new-polymorph-after-24-years.pdf> DOI: 10.26434/chemrxiv-2022-35fwp *

Also Published As

Publication number Publication date
US20240269118A1 (en) 2024-08-15
WO2024050019A2 (fr) 2024-03-07

Similar Documents

Publication Publication Date Title
MX2022008066A (es) Compuestos triciclicos sustituidos.
EP4282416A3 (fr) Procédé de fabrication d&#39;un composé pour inhiber l&#39;activité de shp2
UA97619C2 (ru) Гидрогалогенидный комплекс агомелатина и способ его получения
WO2019027173A3 (fr) Nouvelle psicose-6-phosphate phosphatase, composition pour la production de psicose comprenant ladite enzyme, procédé pour la production de psicose au moyen de ladite enzyme
MX2021012296A (es) Microorganismo que produce l-aminoacido y procedimiento de produccion de l-aminoacido mediante el uso del mismo.
WO2024050019A3 (fr) Procédés de préparation de formes à l&#39;état solide
WO2021178976A3 (fr) Prényltransférases et leurs procédés de préparation et d&#39;utilisation
MX2021006808A (es) Novedosa psicosa-6-fosfato fosfatasa, composicion para la produccion de psicosa que comprende la misma y procedimiento para la produccion de psicosa mediante el uso de la misma.
MX2024001304A (es) Composiciones y metodos para anticuerpos anti-pacap.
WO2023039472A3 (fr) Compositions comprenant une nucléase crispr et ses utilisations
MX2024006783A (es) Compuestos de diazaspiro sustituidos con carbonilo y su uso.
MX2023005954A (es) Procesos para preparar citrato de arimoclomol e intermediarios del mismo.
MX2023000059A (es) Metodo de preparacion de compuesto de fenilisoxazolina.
WO2023122784A3 (fr) Spiros et analogues associés pour inhiber yap/taz-tead
WO2005063731A3 (fr) Production de dihydronepetalactone par reduction de l&#39;acide nepetalique
MX2023011976A (es) Sintesis de compuestos analogos de rapamicina.
WO2022046953A3 (fr) Conversion de puissance nucléaire mixte
MY197373A (en) Methods for optimizing gas utilization
EP4118222A4 (fr) Processus de fermentation permettant la production de lipides
WO2020121324A3 (fr) Procédé de production de nigéricine à partir de streptomyces sp. mcc-0151
WO2023118499A3 (fr) Aliment pour ruminants ou complément pour aliment pour ruminants et son procédé de préparation
CN110759924B8 (zh) 脱镁叶绿酸a甲酯的制备方法
MX2024007898A (es) Metodo para preparar productos que contienen aminoacidos a partir del caldo de fermentacion.
TW202438053A (zh) Ｋｉｆ１８ａ吲哚啉抑制劑之固體調配物及多晶形式
MX2024010151A (es) Produccion de micelio fungico con color.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23801038

Country of ref document: EP

Kind code of ref document: A2